Cardiome Pharma (CRME) Misses Q4 EPS by 25c

Cardiome Pharma (NASDAQ: CRME) reported Q4 EPS of ($0.39), $0.25 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $7 million versus the consensus estimate of $8.54 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c